Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant interferon-alpha + recombinant interleukin-6
- Development stage
- Discontinued
- Lead developer
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
This combination therapy consists of recombinant interferon-alpha (IFN-α) and recombinant interleukin-6 (IL-6), investigated as a 'differentiation therapy' for patients with recurrent multiple myeloma. Interferon-alpha is a cytokine that exerts direct anti-proliferative and pro-apoptotic effects on malignant plasma cells while also enhancing the host's immune response. Interleukin-6, although typically a growth factor for myeloma cells, is used in this specific protocol to potentially induce the differentiation of myeloma cells or sensitize them to the inhibitory effects of interferon-alpha. The treatment was evaluated in clinical trials led by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to determine if the synergistic application of these two cytokines could improve outcomes in patients who had failed multiple prior therapies.
- Other names
- recombinant interferon-alpha and recombinant interleukin-6IL-6 + IFN-alphaDifferentiation therapy (IL-6 and IFN-a)
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on recombinant interferon-alpha + recombinant interleukin-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant interferon-alpha + recombinant interleukin-6.